You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

130 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    procarbazine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab (Unfunded),
methotrexate,
procarbazine,
cytarabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2020
Regimen
Cancer Type:
Endocrine, 
Thyroid
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
gemcitabine,
oxaliplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2020
Guidelines and Advice
Status: Current
Version: 2
Jan 2022
Cancer facts
Jan 2022
Cancer facts
Jan 2022
Guidelines and Advice
Status: Current
ID: PET 2021-1
Jan 2022
Guidelines and Advice
Status: In-Review
ID: GL MOTAC-4
Version: 2
Jan 2022
Guidelines and Advice
Status: In-Review
ID: RR SCT-9
Version: N/A
Jun 2020
Statistical Reports
Aug 2020
Statistical Reports
Aug 2020

Pages